The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six hepatitis C virus (HCV) infected patients.
In this double-blind, randomized, placebo-controlled Phase Ia study, subjects will be treated with single ascending doses of PHX1766 in order to assess safety, tolerability and pharmacokinetics. Additionally, reductions in viral load will be measured in the patients with HCV infection.
Julie Cherrington, president of Phenomix, said: “We expedited our HCV discovery program and have designed a unique Phase Ia program in order to obtain single day safety, tolerability and viral load information for PHX1766. We believe our HCV protease inhibitor PHX1766 will be distinguished by its favorable dosing, potency and selectivity attributes.”